Related Experiment Video
Updated: May 17, 2026
07:01
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
Towards microRNA-based therapeutics for diabetic nephropathy
1Diabetes, Cardiovascular and Metabolic Diseases Division, Translational Genomics Research Institute, 445 North Fifth St, Phoenix, AZ 85004, USA.
Diabetologia
|November 9, 2012
Summary
Diabetic nephropathy lacks a cure, but microRNAs (miRNAs) show promise. Targeting specific miRNAs in animal models reduced disease markers, suggesting potential new therapies for diabetic kidney disease.
Area of Science:
- Molecular Biology
- Genetics
- Nephrology
Background:
- Diabetic nephropathy has no cure, and its molecular causes are unclear.
- Current treatments delay but do not halt progression for many patients, leading to renal failure.
- Novel therapeutic targets are crucial for treating and preventing diabetic nephropathy.
Purpose of the Study:
- To explore microRNAs (miRNAs) as potential therapeutic targets for diabetic nephropathy.
- To investigate the role of miRNA dysregulation in the development of diabetic nephropathy.
- To assess the feasibility of miRNA-based therapeutics for diabetic kidney disease.
Main Methods:
- Reviewing evidence on miRNA involvement in human diseases and diabetic nephropathy.
- Examining studies on in vivo miRNA modulation and clinical trial results.
- Analyzing animal model data where miRNA inhibition impacts disease markers.
Main Results:
- MicroRNA dysregulation is implicated in various human diseases, including emerging evidence in diabetic nephropathy.
- Inhibition of upregulated miRNAs in animal models reduced albuminuria and mesangial matrix accumulation.
- Successful clinical trials demonstrate the feasibility of in vivo miRNA modulation.
Conclusions:
- MicroRNAs represent promising therapeutic targets for diabetic nephropathy.
- Further research and development of delivery systems are needed for miRNA-based treatments.
- Understanding miRNA roles may lead to improved therapies for diabetic kidney disease.
Related Concept Videos
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...